Form 4 for LBRX LB PHARMACEUTICALS INC
Accepted 2025-09-16 00:00:00 ET · period of report 2025-09-12 · accession 0002015536-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-16 | 2025-09-12 | LBRX | Deep Track Capital, LP | 10% | C - Cnv Deriv | — | +686.1K | 686.1K | New | — |
| D | 2025-09-16 | 2025-09-12 | LBRX | Deep Track Capital, LP | 10% | P - Purchase | $15.00 | +2.00M | 2.69M | +291% | +$30.00M |
| DI | 2025-09-16 | 2025-09-12 | LBRX | Deep Track Capital, LP | 10% | P - Purchase | $15.00 | +666.7K | 666.7K | New | +$10.00M |
| D | 2025-09-16 | 2025-09-12 | LBRX | Deep Track Capital, LP | 10% | C - Cnv Deriv | — | -16.67M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-12 | C | A | 686,138 | — | 686,138 | D | — | — | (F1) Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering. (F2) Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. |
| 2 | Common | Common Stock | 2025-09-12 | P | A | 2,000,000 | $15.00 | 2,686,138 | D | — | — | (F2) Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. |
| 3 | Common | Common Stock | 2025-09-12 | P | A | 666,666 | $15.00 | 666,666 | I By Deep Track Special Opportunities Fund, LP | — | — | (F3) Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. |
| 4 | Derivative | Series C Preferred Stock | 2025-09-12 | C | D | 16,666,667 | — | 0 | D | — · — to — | 686,138 Common Stock | (F1) Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering. (F2) Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. |